Protein A affinity chromatography: the 'gold standard' for antibody purification and its new evolution powered by AI

In fields like biopharmaceuticals, immune testing, and antibody development, the efficiency, purity, and stability of antibody purification directly determine experimental results and product quality. Protein A affinity chromatography, as the most widely used and mature core technique for antibody purification globally, has become the preferred method for purifying monoclonal antibodies, polyclonal antibodies, and Fc fusion proteins due to its high specificity and high recovery rate.

Shanghai Matwings Technology's AI-driven protein R&D platform, MatwingsVenus™ (Xiaowu™), leverages its self-developed large protein design model to deeply explore protein purification media and ligand development. By relying on engineering modification techniques and standardized production processes, it has developed high-performance Protein A series purification products that are precisely tailored for both research experiments and industrial-scale antibody purification, addressing industry pain points like unstable traditional purification processes, poor alkali resistance, and insufficient purity.

I. Core Mechanism: How does Protein A achieve precise antibody capture?

 Molecular Principles of Protein A Affinity Chromatography

Protein A, full name Staphylococcal Protein A (SPA), is a surface protein found on the cell wall of Staphylococcus aureus. It naturally has a special ability—it can specifically recognize the conserved site at the junction of the CH2-CH3 domains on the Fc region of immunoglobulin G (IgG), showing high affinity for human IgG1, IgG2, and IgG4 subclasses, but it doesn’t bind or binds weakly to IgG3, IgM, IgA, and other antibody types. Natural Protein A contains five homologous IgG-binding domains (E, D, A, B, C), while commercial recombinant ligands typically use engineered B domains (i.e., Z domains) or C domains as the backbone.

By coupling recombinant Protein A ligand proteins to solid supports like agarose gel, you can make Protein A resins (also referred to in academic contexts as Protein A affinity chromatography media or Protein A purification media). When a complex sample containing antibodies (such as cell culture supernatant, ascites, or serum) flows through the column, the antibodies are specifically captured by the ligand, while other contaminant proteins flow straight through. By subsequently changing conditions such as pH, you can elute highly pure antibodies. With just a single step of affinity chromatography, you can obtain high-purity antibodies—this is exactly the core value of Protein A affinity chromatography.

After decades of development, Protein A affinity chromatography has become the preferred method for antibody purification, with three main advantages:

High specificity: It only binds the Fc fragment of IgG and almost does not adsorb host cell proteins, nucleic acids, or medium components, achieving over 95% purity in a single step.

High recovery: The binding conditions are gentle and do not damage antibody structure, and the antibody activity is well preserved after elution, with typical recovery rates over 90%.

Ease of operation: The four-step process of loading–washing–elution–cleaning is highly standardized and easily scalable from laboratory to industrial production.

These features have kept Protein A affinity chromatography at the 'core position' of antibody purification over the past decades—from milligram-scale lab prep to commercial ton-scale antibody production, various Protein A chromatography media and purification media remain key consumables throughout the entire process.

II. Product System: Clarifying Core Concepts and Hierarchical Relationships

Around the Protein A technology system, there are several professional names in the industry. Although they seem similar, they actually point to different levels, together forming a complete purification technology and material system.

1. Protein A affinity chromatography (core technology process)

A mature set of biological separation and purification technology principles and process flows includes optimization of a series of parameters such as sample loading flow rate, buffer formulation, elution pH, and Clean-in-Place (CIP) conditions. The core is to utilize the specific reversible binding properties of Protein A ligands to the antibody Fc segment, and through a standardized "binding–cleaning–elution–regeneration" process, precisely enrich and purify antibody proteins from complex samples. With the advantages of high specificity and high purification multiple, high-purity antibody enrichment can be achieved in a single purification, making it the core process for industrial antibody capture in biopharmaceuticals.

2. Protein A Ligand Protein (Core Functional Ingredient)

The Protein A protein molecule itself is the "source of function," determining the antibody-binding capacity, alkali resistance, and lifespan of the filler. Wild-type Protein A is naturally expressed by Staphylococcus aureus, while most commercial Protein A ligands are genetically engineered recombinant proteins—for example, introducing cysteine at the C-terminal for targeted conjugation or introducing targeted mutations to enhance alkali resistance.

3. Protein A affinity chromatography medium / Protein A chromatography medium / Protein A packing / Protein A purification medium (final application carrier)

A functional separation medium that specifically conjugates modified Protein A ligands onto solid carriers such as agarose and acrylic resin is a core consumable for antibody purification. In academic terms, these are often referred to as "chromatography media" or "purification media," while in industrial practice they are commonly referred to as "packing materials." Both refer to the same physical entity and can be directly loaded onto the affinity chromatography column for use.

Simply put, Protein A ligand protein is the "soul," determining binding activity and stability; Protein A packing (also known as Protein A affinity chromatography medium or Protein A purification medium) is the "body" that determines flow rate, backpressure, and column loading performance; Protein A affinity chromatography is the complete "operating procedure." All three are progressively advanced, and none can be omitted.

III. Industrial Challenge: Alkali Resistance—The 'Life-and-Death Question' of Protein A Fillers

If there is one metric to measure the industrial value of Protein A fillers, it must be alkali resistance.

The reason is straightforward: in large-scale antibody production, the number of times the resin can be reused directly determines production costs. After each use, the resin needs to undergo cleaning-in-place (CIP)—usually treated with 0.1M to 1M NaOH solution to remove residual host cell proteins, endotoxins, viruses, and other contaminants, ensuring product quality and safety between batches.

However, wild-type Protein A has a natural weak spot: under high pH (strong alkaline) conditions, its protein structure tends to unfold, resulting in reduced or even lost antibody binding capacity. This means that with each CIP cycle, the resin's performance deteriorates, and after dozens of uses, the entire chromatography column needs to be replaced. For antibody production at a fermentation scale of thousands of liters, frequent resin replacement equals huge costs.

Because of this, the industry has been continuously using various strategies over the years to engineer Protein A ligands to improve their alkaline resistance:

1. Site-directed mutagenesis: Replace alkaline-sensitive asparagine (Asn) and glutamine (Gln) residues with more stable amino acids to reduce deamidation breakdown under alkaline conditions.

2. Structural stabilization: Introduce additional disulfide bonds or salt bridges to increase overall structural rigidity and reduce the tendency to unfold at high pH.

3. Directed coupling: Introduce cysteine at the C-terminus of Protein A to achieve oriented fixation of the ligand on the microsphere surface, so all ligand molecules are correctly oriented, which increases the proportion of active binding sites and reduces structural instability caused by random coupling.

Several semi-rational design studies have shown that Protein A mutants modified using these combined strategies can retain over 80% of their dynamic binding capacity (DBC) after 0.5M NaOH treatment for 24 hours, raise melting temperature (Tm) by 2–3°C, increase α-helix content, and significantly enhance protein structural stability. Some studies even found that for certain highly alkaline-tolerant Protein A resins, moderate alkaline treatment can actually further boost dynamic binding capacity by altering mass transfer mechanisms—indicating that alkaline resistance is not just about "withstanding" harsh conditions; it can be a finely tunable engineering variable.

IV. AI-Driven: From “Trial and Error” to “Smart Design”

1. Limitations of traditional modification methods

Traditional Protein A ligand modifications follow the "rational design and directed evolution" path: based on structural biology insights, key residues are predicted, mutation libraries are constructed, and then mutants with better alkaline resistance are screened experimentally. This process typically takes months or even years, relies heavily on experts’ structural knowledge and judgment, and the combination space of mutations is huge, making it difficult to explore systematically.

2. AI-Driven Design Logic

Matwings Technology's self-developed general AI for protein design breaks through the limits of structure prediction methods like AlphaFold, which can only predict structures but can't design functions. It can directly design protein sequences based on functional requirements. The MatwingsVenus™ (Xiaowu™) platform takes this further by integrating a database with billions of real protein labels, over 200 specialized protein design tools, and more than 30 expert-tuned skills, creating a "conversational protein R&D AI." Researchers can simply enter performance goals in natural language, such as alkali resistance or binding activity, and the AI will handle intelligent sequence design. It then links automatically to the lab for sample prep, protein purification, and functional testing, forming a "design-verify-iterate" loop that significantly shortens the R&D cycle.

3. From AI Design to High-Performance Products

 Protein A affinity chromatography resin 

Based on the AI-driven design platform mentioned above, Matwings Technology’s MatwingsVenus™ (Xiaowu™) has launched the iteratively upgraded Protein A series products, transforming smart design results into Protein A affinity ligands that can be supplied at scale:

- Super alkaline resistance, suitable for harsh CIP processes: The AI-designed modified Protein A ligand proteins can withstand conventional cleaning and regeneration with 1M NaOH. After repeated regeneration, the dynamic binding capacity shows no significant decline, effectively extending the lifespan of Protein A resins and significantly reducing consumable costs in industrial production. They also offer broad pH tolerance, maintaining stable purification performance in both acidic and alkaline environments without protein degradation or activity loss.

- High purity and high activity: Using a proprietary purification process, the purity of the ligand protein remains stably above 95%, with host cell proteins (HCP), endotoxins, nucleic acids, and other impurities strictly controlled within pharmacopeia standards. As a Protein A purification medium, it has strong specific binding capability and can efficiently purify monoclonal antibodies, polyclonal antibodies, and various Fc-fusion recombinant proteins, meeting both research and industrial purity requirements in just one step.

- Standardized production and flexible supply: The platform supports GMP-level production, strictly following a standardized quality control system with strong batch stability. It also supports custom specifications, offering multiple sizes of products from laboratory-scale trials to industrial-scale production, ensuring long-term stable supply for customers.

V. Industry Value: Looking at supply chain autonomy and control from just one resin.

 Industrial-scale antibody purification and production scenarios

A Protein A resin column may seem like just a consumable, but behind it lies the cost structure of the entire antibody pharmaceutical industry.

In antibody production, downstream purification accounts for about 30–50% of total production costs, and Protein A affinity chromatography takes up 50–70% of that purification cost. In other words, Protein A affinity chromatography is the biggest chunk of purification expense. The lifespan, binding capacity, and price of the resin—all directly affect the final production cost per gram of antibody. Rough industry estimates suggest that a resin that can withstand 100 more CIP cycles or has 20% higher capacity could mean millions to tens of millions in cost difference at the kilogram-scale production level.

Globally, the Protein A resin market was around $1.8 billion in 2025 (according to Research and Markets), and is expected to surpass $2 billion by 2030, with a compound annual growth rate of about 6–8%. This huge market has long been dominated by a few international giants. In China, the biopharmaceutical chromatography media market reached 10.8 billion yuan in 2025, showing immense potential for domestic alternatives.

Today, domestic companies like Matwings Technology are breaking this pattern through the approach of 'AI-assisted design and independent engineered production.' From 'usable' to 'easy-to-use,' from 'following' to 'running alongside,' the replacement process of high-performance domestic Protein A products reflects a microcosm of a self-reliant Chinese biopharmaceutical supply chain.

The deeper significance is this: if AI can efficiently improve Protein A ligands, it can also transform industrial enzymes, therapeutic antibodies, food proteins… Protein A is just the starting point. When protein engineering shifts from 'expert experience-driven' to 'AI data-driven,' all industries relying on protein performance will experience a systematic leap in efficiency.

VI. Conclusion

From the naturally occurring Protein A found in Staphylococcus aureus, to the gene-engineered expression of recombinant Protein A, and now to AI-driven precise design and engineering implementation—Protein A affinity chromatography, this classic technique, is undergoing a profound shift from being "experience-driven" to "AI-intelligence-driven."

Shanghai Matwings Technology's MatwingsVenus™ (Xiaowu™) platform is deeply focused on core AI protein design technologies, offering engineered Protein A ligand proteins with high alkali resistance, high activity, and high stability, along with a series of Protein A affinity chromatography media (resins/purification media). These provide researchers and biopharmaceutical companies with efficient, reliable, and cost-effective integrated antibody purification solutions. With the continuous growth of antibody therapeutics, more efficient, stable, and economical Protein A chromatography and purification media are moving from AI "design blueprints" to industrial "production reality" at an accelerating pace.